Ain Shams University
Cairo, 11591, Egypt
Location status: Recruiting
Location contact
Ahmed G Abdellattif, MD
PRINCIPAL_INVESTIGATOR
Mina G Basta, MD
PRINCIPAL_INVESTIGATOR
Mohamed A Hagag, MD
CONTACT
NCT Number: NCT07678697
This study aims to compare the efficacy (in terms of vein clearance) and safety of Nd:YAG laser combined with injection sclerotherapy versus diode laser combined with injection sclerotherapy in the treatment of reticular veins and telangiectasias using the Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique.
Interested in participating?
Request Info18 year–60 year
All sexes
Interventional
Not applicable
Cairo, 11591, Egypt
Location status: Recruiting
Ahmed G Abdellattif, MD
PRINCIPAL_INVESTIGATOR
Mina G Basta, MD
PRINCIPAL_INVESTIGATOR
Mohamed A Hagag, MD
CONTACT
Reticular veins and telangiectasias (spider veins) represent common chronic venous disorders affecting a large proportion of the adult population, particularly women.
The Cryo-Laser and Cryo-Sclerotherapy (CLaCS) technique has emerged as an innovative method combining transdermal laser therapy, injection sclerotherapy, and skin cooling. This multimodal approach enhances visualization of feeder veins using augmented reality or vein illumination systems, allowing precise targeting and improved clearance rates. Cooling reduces pain and protects the epidermis, making the procedure more tolerable and safer.
Nd:YAG laser (1064 nm) is considered the cornerstone of the CLaCS technique due to its deeper penetration and selective photothermolysis of hemoglobin. It effectively targets deeper reticular veins (up to 3-4 mm depth), induces vessel wall contraction, and facilitates subsequent sclerotherapy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will receive Nd:YAG laser (1064 nm) + injection sclerotherapy (CLaCS).
Patients will receive Diode laser (980 nm) + injection sclerotherapy (CLaCS).
Time frame: 6 months postoperatively
Degree of vein clearance will be assessed by immediate endpoint response during laser application, defined as either instantaneous disappearance of the vein or an immediate change in vein color.
Time frame: 6 months postoperatively
Each patient will be instructed about postoperative pain assessment with VAS. VAS (0 represents "no pain" while 10 represents "the worst pain imaginable").
Time frame: 6 months postoperatively
Degree of patient satisfaction will be assessed on a 5-point Likert scale patient satisfaction (1, extremely dissatisfied; 2, unsatisfied; 3, neutral; 4, satisfied; 5, extremely satisfied).
Time frame: 6 months postoperatively
Incidence of complications such as hyperpigmentation, burns, and matting will be recorded.
Time frame: 6 months postoperatively
Number of treatment sessions required will be recorded.
Time frame: 6 months postoperatively
Recurrence rate will be recorded.
Contact information is provided by the study sponsor or research team.
Ain Shams University
Other
Comparative Study Between Nd:YAG Laser Combined With Injection Sclerotherapy Versus Diode Laser in the Treatment of Reticular Veins and Telangiectasias Using CLaCS Technique
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06962813
Cardiovascular Diseases, Telangiectasias
São Paulo, Brazil
View Trial DetailsNCT02761174
Cardiovascular Diseases, Inflammation
Copenhagen NV, Denmark
View Trial DetailsNCT07601425
Arteriovenous Malformations, Cardiovascular Abnormalities
Boston, Massachusetts, United States
View Trial DetailsNCT06259292
Arteriovenous Malformations, Brain Diseases
Birmingham, Alabama, United States
View Trial Details